ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
Market Cap
—
MomentumView details →
1D Return
—
YTD Return
—
RSI (14)
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
Market Cap
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Jun 1, 2026
Novartis AG (NYSE:NVS) is a Swiss multinational pharmaceutical corporation founded in 1996 through the merger of Ciba-Geigy and Sandoz. Headquartered in Basel, Switzerland, Novartis has evolved into one of the world's largest pharmaceutical companies, focusing on innovative prescription medicines across multiple therapeutic areas. The company completed a significant strategic transformation in 2023 by spinning off its generics division Sandoz, allowing it to focus entirely on developing and commercializing breakthrough treatments for serious diseases.
Latest newsMore news →
Novartis shares slumped 11% in one day, wiping nearly $30 billion off its market value, after the failure of the muscle-wasting disorder drug del-desiran in a late-stage study.2d agoIn US after-hours trading on September 11, 2026, most pharmaceutical and biotech stocks rose, with Eli Lilly up 0.03%, Johnson & Johnson up 0.32%, Merck up 0.09%, Novartis up 0.14%, AstraZeneca up 0.38% and Novo Nordisk up 0.11%.3d agoArtisan Partners, a shareholder of Novartis AG, publicly urged the Swiss drugmaker to shake up its board and overhaul its M&A approach after share declines following three clinical trial setbacks.3d ago